ClinicalTrials.gg
CompletedNCT03275025Updated May 3, 2021

A Phase 2 Study to Evaluate the Safety and Efficacy of YRA-1909 in Patients With Rheumatoid Arthritis

A Phase 2 interventional study of YRA-1909 low dose and YRA-1909 mid dose in Rheumatoid Arthritis, sponsored by Yungjin Pharm. Co., Ltd.. Completed at 14 sites in Korea, Republic of. Open to participants aged 19 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-05-03.

Sponsored by Yungjin Pharm. Co., Ltd. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Apr 2017, registered Aug 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
116
Allocation
Randomized
Ages
19 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 188 studies in Arthritis, Rheumatoid with a site in Korea, Republic of — 10 open to participants now, 16 under way, 2 of them phase 3. Arthritis, Rheumatoid · Korea, Republic of.

Enrollment
111th of 155
116 · median 300
Started
2017
with 6 others
Phase 2
30 of 188
1 open now
Registered
148th of 188
by date

Among the 188 studies in Arthritis, Rheumatoid with a site in Korea, Republic of, this one is the 111th largest by enrollment of the 155 interventional ones that give a count, is one of 7 that started in 2017, is one of 30 in phase 2, and was the 148th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

10 of the 188 studies in Arthritis, Rheumatoid with a site in Korea, Republic of are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 19 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 188 studies in Arthritis, Rheumatoid with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This is a multicenter, randomized, double-blind phase2 study to evaluate the safety and investigate the efficacy of YRA-1909 in Patients with Rheumatoid Arthritis who are on a stable dose of Methotrexate(MTX) and who have an inadequate response to MTX(MTX-IR).

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
19 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 19 Years to 80 Years
  • Subjects with onset RA classified by ACR/EULAR 2010 revised classification criteria at least 12 weeks prior to screening
  • Subjects meet the ACR 1992 Revised Criteria for the Classification of Global Functional Status in RA Class I, II or, III at screening

Exclusion criteria

Exclusion Criteria:

  • Subjects meet the ACR 1992 Revised Criteria for the Classification of Global Functional Status in RA Class Ⅳ at screening
  • Any of the following laboratory values at screening:

    1. Patients with severe liver impairment ( or ALT > 2 times the )
    2. Patients with renal disease,immunodeficiency disease and peptic ulcer
    3. Patients with pleural effusion and ascites
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
116 participants (actual)

Study arms

  • Experimental
    YRA-1909 low dose

    Drug: YRA-1909 low dose · Drug: Placebo

  • Experimental
    YRA-1909 medium does

    Drug: YRA-1909 mid dose · Drug: Placebo

  • Experimental
    YRA-1909 high dose

    Drug: YRA-1909 high dose

  • Placebo comparator
    YRA-1909 Placebo

    Drug: Placebo

Interventions

  • DrugYRA-1909 low dose

    A low dose of YRA-1909; daily oral intake for 12 weeks

  • DrugYRA-1909 mid dose

    A mid dose of YRA-1909; daily oral intake for 12 weeks

  • DrugYRA-1909 high dose

    A high dose of YRA-1909; daily oral intake for 12 weeks

  • DrugPlacebo

    Matching placebo dosing with daily oral intake for 12 weeks

06

What researchers measure

Primary outcomes

  1. American College of Rheumatology 20 (ACR20) response rate at Week 12

    Time frame: Week 12

  2. Percentage of Participants With Adverse Events

    Incidence of all grade adverse events

    Time frame: Week 12

Secondary outcomes

  1. ACR20 Response at Week 4,8

    Time frame: Week 4 and 8

  2. Change From Baseline in Patient Assessment of Pain Visual Analog Scale (VAS) at Week 4,8 and 12

    Time frame: Week 4,8 and 12

  3. ACR 50, 70 Response at Week 4, 8 and 12

    Time frame: Week 4, 8 and 12

  4. Mean Percent Change From Baseline in the Swollen Joint Count(SJC) and Tender Joint Count (TJC) at Week 4, 8 and 12

    Time frame: Week 4, 8 and 12

  5. Change From Baseline in Erythrocyte Sedimentation Rate (ESR) at Week 4, 8 and 12

    Time frame: Week 4, 8 and 12

  6. Change From Baseline in High Sensitivity C-Reactive Protein (hsCRP) at Week 4, 8 and 12

    Time frame: Weeks 4, 8 and 12

  7. Mean Change from Baseline in Assessment of participant's illness at Week 4, 8 and 12 by participants and investigator/sub-investigator

    Time frame: Week 4, 8 and 12

07

Study locations

14 sites
  • Seoul National University Hospital
    Seoul, Jongno-gu 110744, Korea, Republic of
  • Hanllym University Medical Center
    Anyang, Korea, Republic of
  • Chungbuk National University Hospital
    Chungju, Korea, Republic of
  • Kelmyung University Dongsan Medical Center
    Daegu, Korea, Republic of
  • Chungnam National University Hospital
    Daejeon, Korea, Republic of
  • Kyung Hee University Hospital at Gangdong
    Gangdong, Korea, Republic of
  • Chonnam National University Hospital
    Gwangju, Korea, Republic of
  • Gachon University Gil Medical Center
    Incheon, Korea, Republic of
  • Chonbuk National University Hospital
    Jeonju, Korea, Republic of
  • Seoul National University Bundang Hospital
    Seongnam, Korea, Republic of
  • Hanyang University Seoul Hospital
    Seoul, Korea, Republic of
  • KyungHee University Hospital
    Seoul, Korea, Republic of
  • Seoul Metropolitan Goverment Seoul National Univeersity Boramae Medical Center
    Seoul, Korea, Republic of
  • Ajou University Hospital
    Suwon, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2017 to primary completion in Nov 2019, 31 months.

Of 116 industry-sponsored phase 2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 24. This study's 31 months is above that.

Counting every sponsor, half of 158 studies reached it within 18 months; a quarter within 13 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2017
First posted
Sep 7, 2017
StartActual
Apr 1, 2017
Primary completionActual
Nov 19, 2019
CompletionActual
Nov 19, 2019
Last update
May 3, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 3, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03275025
Lead sponsor
Yungjin Pharm. Co., Ltd.
Responsible party
Sponsor
First posted
Sep 7, 2017
Start date
Apr 1, 2017
Primary completion
Nov 19, 2019
Completion
Nov 19, 2019
Last update
May 3, 2021

Study contacts

YeongWook Song, M.D.,Ph.D.
study chair · Seoul National University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion